Hepatocellular Carcinoma (## Hepatocellular Carcinoma (HCC) – Academic Authority & Transplant-Centric Control

Hepatocellular Carcinoma (## Hepatocellular Carcinoma (HCC) – Academic Authority & Transplant-Centric Control

ESMO-aligned, evidence-driven positioning under clinical command.

Dr Chetan Kalal leads a rigorously structured, transplant-forward management framework for Hepatocellular Carcinoma (HCC), integrating contemporary oncologic standards with advanced hepatology and surgical decision precision. The approach is benchmarked against international guidelines (ESMO / AASLD principles) while remaining grounded in real-world transplant feasibility.

Clinical Architecture of HCC Care

• Comprehensive staging with dynamic contrast MRI/CT, LI-RADS classification, AFP kinetics and functional reserve assessment (Child-Pugh, MELD, ALBI)

• Multidisciplinary tumour board model incorporating hepatology, transplant surgery, interventional radiology and oncology

• Curative-intent pathway prioritising:

  • Liver Transplantation (Definitive therapy for early-intermediate HCC in cirrhotic liver)

  • Surgical Resection where criteria permit

  • Image-guided ablation (RFA/MWA) in strictly selected scenarios

Transplant Dominance Philosophy

HCC under Dr Kalal is not treated as an isolated malignancy but as a systemic hepatic failure continuum requiring definitive organ replacement when indicated. Transplant eligibility is evaluated using:

• Milan & Expanded Criteria stratification

• Biological tumour behaviour profiling

• Response-to-bridging therapy monitoring

• Recurrence risk modelling

This ensures:

• Lower post-transplant recurrence rates

• Improved long-term survival indices

• Controlled oncologic burden pre-transplant

Integrated IPD Emergency Pathway for HCC

• Rapid admission for decompensated cirrhosis with tumour burden

• Urgent evaluation for transplant candidacy

• Stabilisation protocols for ascites, variceal bleed, hepatic encephalopathy

• Priority coordination with transplant teams

This is not volume-based oncology. This is precision hepatology with curative dominance.

Dr Chetan Kalal’s management of HCC reflects an evidence-led, transplant-centric philosophy aligned with global oncology standards, engineered to deliver maximal survival advantage with minimal therapeutic compromise.

For high-risk HCC patients, delayed intervention is not an option. Structured action is.### Clinical Power with Controlled Dominance

HCC is not a diagnosis. It is a battlefield — and hesitation kills outcomes.

Dr Chetan Kalal leads a precision-driven, protocol-governed HCC management pathway designed for aggressive control, survival optimisation, and when indicated, curative transplant intent. This unit is engineered for high-risk cirrhotic patients and advanced liver cancer cases requiring decisive, multidisciplinary escalation.

What Sets This HCC Program Apart

1. Transplant-Intent Oncology Strategy
Every eligible HCC patient is evaluated through a transplant-first lens — not palliative drift. Milan, UCSF and expanded criteria are assessed with real-time imaging and dynamic lab integration.

2. Rapid Stratification & Staging Protocol

• Same-day AFP, Triphasic CT / Liver MRI evaluation

• BCLC staging with treatment mapping

• Immediate MDT decision loop

3. Integrated Treatment Arsenal

• Curative pathway: Liver Transplantation | Surgical Resection | Local Ablation

• Disease control: TACE | TARE | Immunotherapy coordination

• Bridge-to-transplant protocols with continuous surveillance

4. IPD-Centric Cancer Command Model
Complex HCC cases are admitted early — not after collapse. Continuous monitoring, complication control, nutrition optimisation and portal hypertension stabilisation occur within a single command structure.

For High-Risk & Advanced HCC Patients

This program is built for:

• Rapidly progressive tumours

• Decompensated cirrhosis with HCC

• Failed prior therapies

• International patients seeking second opinion or transplant evaluation

Not Every HCC Needs Delay. Some Need Authority.

If you or your patient has been told to "wait and watch" — question that advice. HCC progression is unforgiving. Here, decisions are data-driven, time-sensitive and outcome-obsessed.

📍 Mumbai | Navi Mumbai | Thane | Bandra | Juhu | Andheri | South Mumbai
🌍 International HCC Consults & Transplant Evaluation — Virtual + Fast-track Admission

Dr Chetan Kalal
India’s leading Hepatologist & Liver Transplant Physician
First DM Hepatologist of Maharashtra

🔗 Priority HCC Admission & Oncology Referral: drchetankalal.com 📞 IPD Coordination Desk | Emergency Oncology Support